A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited efficacy against glioblastoma—the deadliest type of ...
Mar 13, 2023
0
65
Unlike other forms of blood cancer, acute myeloid leukemia (AML) cannot currently be treated with CAR-T cell immunotherapy. The reason is that specific molecular targets with which certain immune cells could specifically ...
Mar 13, 2023
0
51
Scientists from German Cancer Research Center (DKFZ), together with colleagues from Germany, Israel, and the U.S., have found that the gut microbiome may modulate the efficacy of CAR-T cellular immunotherapy CAR-T cells in ...
Mar 13, 2023
0
71
Blood cancer patients, especially when they relapse, have a poor prognosis, and generally do not survive very long. The last five years have seen success in treating these patients with Chimeric Antigen Receptor (CAR) T-cells—a ...
Feb 24, 2023
0
50
Universitätsklinikum Erlangen is the first in the world to use CAR T-cells to successfully treat a patient suffering from a severe case of muscle inflammation (myositis). The disease is triggered by a malfunction in the ...
Feb 20, 2023
0
104
New adoptive T cell therapies—in which T cells, the immune system's natural hunters patrolling the body for foreign adversaries, are retrieved from cancer-riddled patients, super-charged and amplified outside the body, ...
Feb 10, 2023
0
59
A team of medical specialists working at Memorial Sloan Kettering Cancer Center in New York has found that donated white blood cells can be used effectively as part of CAR T cell therapy to treat myeloma patients.
Inhibiting a particular protein in cancer-killing immune cells might improve the long-term effectiveness of CAR T-cell and other immune checkpoint therapies, according to a new study by researchers at The Ohio State University ...
Jan 24, 2023
0
53
The recent years have seen a wave of adoptive cell therapies (ACTs), a type of immunotherapy in which T cells (T cell transfer therapy) and other immune cells are obtained from patients, activated and multiplied outside the ...
Jan 10, 2023
0
53
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types ...
Jan 9, 2023
0
35
